SCHEMBL16596142

SCHEMBL16596142

CCc1cccc(C(=O)N2CCN(C(=O)C(=O)c3c[nH]c4c(-c5ccco5)ccc(OC)c34)CC2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.49
CYP3A4 P08684 2/20 0.46
CYP2D6 P10635 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C8 P10632 1/20 0.44
CYP2B6 P20813 1/20 0.44
CYP2C19 P33261 1/20 0.44
KCNH2 Q12809 1/20 0.44
TUBB4A P04350 1/20 0.44
TUBB P07437 1/20 0.44
TUBA3C P0DPH7 1/20 0.44
TUBA1B P68363 1/20 0.44
TUBA4A P68366 1/20 0.44
TUBB4B P68371 1/20 0.44
TUBB3 Q13509 1/20 0.44
TUBB2A Q13885 1/20 0.44
TUBB8 Q3ZCM7 1/20 0.44
TUBA3E Q6PEY2 1/20 0.44
TUBA1A Q71U36 1/20 0.44
TUBA1C Q9BQE3 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23967333 0.90 CYP2C9 (0.52) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL12788260 0.90 CYP2C9 (0.51) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL6442368 0.89 CYP2C9 (0.62) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL15360310 0.84 CYP2C9 (0.46) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL13554673 0.81 CYP2C9 (0.52) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL15360328 0.79 CYP2C9 (0.43) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL13554770 0.77 CYP2C9 (0.40) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL8530617 0.77 CYP2C9 (0.59) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL23387038 0.76 CYP2C9 (0.57) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8
SCHEMBL18473669 0.76 CYP2C9 (0.61) CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150087609-A1 CYTOTOXIC-DRUG DELIVERING MOLECULES TARGETING HIV (CDM-HS), CYTOTOXIC ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USE YALE UNIVERSITY 2015-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150087609-A1 CYTOTOXIC-DRUG DELIVERING MOLECULES TARGETING HIV (CDM-HS), CYTOTOXIC ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USE CD4, HAVCR2, CD74 CYP2C9 3179/4885CYP3A4 1302/4885CYP2D6 1290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.